Furthermore, the combination of CTLA-4 blockade and 4-1BB (CD137) activation enhanced tumor rejection by increasing T-cell infiltration, proliferation capacity, and cytokines production [120]. The gene discussed is TNFRSF9; the disease is neoplasm.